PDF
ePub
Citation
Print
Abstract
Background
This study was performed to investigate the difference in high sensitivity C-reactive protein (hsCRP) and metabolic syndrome according to the fasting glucose level, especially between the groups of less than 100 mg/dL and 100–109 mg/dL, which were conventionally categorized into normal levels.
Methods
Those who underwent routine medical checkups aged above 20 (male, 3,221; female, 3,334) at a Health Promotion Center (Seoul, Korea) were divided into normal fasting glucose group I (glucose <100 mg/dL), normal fasting glucose group II (glucose, 100–109 mg/dL), impaired fasting glucose group, and diabetes mellitus group. The hsCRP, obesity index, blood pressure, total cholesterol, triglyceride, high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] were compared among the groups. The hsCRP and the components of metabolic syndrome were compared.
Results
The hsCRP level, age, obesity index, blood pressure, total cholesterol and triglyceride significantly increased along with the increment in fasting glucose level in the 4 groups. The hsCRP had a positive correlation with the fasting glucose level, age, and systolic blood pressure, while it had a negative correlation with HDL-C. The metabolic syndrome was more common in the group with a higher level of glucose.
Conclusions
The group with glucose level of less than 110 mg/dL, conventionally categorized into normal range, needs to be subdivided into a group of 100–109 mg/dL and a group of less than 100 mg/dL. The former group seems to require more efforts to have the glucose level to be maintained under the level of 100 mg/dL.
References
1. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107:499–511.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115–26.
3. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol. 2001; 88:10–5.
4. Lin Y, Rajala MW, Berger JP, Moller DE, Barzilai N, Scherer PE. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem. 2001; 276:42077–83.
5. Roberts WL. CDC/AHA workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice laboratory tests available to assess inflammation-performance and standardization. Circulation. 2004; 110:572–6.
6. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the west of Scotland coronary prevention study. Diabetes. 2002; 51:1596–600.
7. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation. 2003; 107:391–7.
8. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004; 109:2818–25.
9. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26:3160–7.
10. Aronson D, Bartha P, Zinder O, Kerner A, Shitman E, Markiewicz W, et al. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet Med. 2004; 21:39–44.
11. Nakanishi N, Shiraishi T, Wada M. Association between fasting glucose and C-reactive protein in a Japanese population: the Minoh study. Diabetes Res Clin Pract. 2005; 69:88–98.
12. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362:801–9.
13. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999; 100:96–102.
14. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107:363–9.
15. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004; 109:1955–9.
16. Guerrero-Romero F, Rodriguez-Moran M. Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. Diabetes Metab. 2003; 29:65–71.
17. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 1999; 19:1986–91.
18. Alpizar E, Spicer LJ. Effects of interleukin-6 on proliferation and follicle-stimulating hormone-induced estradiol production by bovine granulosa cells in vitro: dependence on size of follicle. Biol Reprod. 1994; 50:38–43.
19. Tseng CH. Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan. Diabetes Care. 2004; 27:517–21.
20. Shai I, Schulze MB, Manson JE, Stampfer MJ, Rifai N, Hu FB. A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes. Diabetologia. 2005; 48:2691–2.
21. Unluhizarci K, Muhtaroglu S, Kabak S, Bayram F, Kelestimur F. Serum lipoprotein(a) levels in patients with diabetic foot lesions. Diabetes Res Clin Pract. 2006; 71:119–23.
22. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Perdersen TR, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Cardiol. 2004; 93:136–41.
23. Ninomiya JK, L'ltalien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004; 109:42–6.
24. Marroquin OC, Kip KE, Kelley DE, Johnson BD, Shaw LJ, Bairey Merz CN, et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation. 2004; 109:714–21.
25. Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcil M, Lesperance J, et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol. 2004; 93:159–64.
Fig. 1.
Prevalence of metabolic syndrome according to fasting glucose level. P<0.01 for the χ2 tests among 4 groups.
Table 1.
Clinical and biochemical characteristics of the subjects according to gender and fasting glucose level
Abbreviations: NR I, normal fasting glucose group I (fasting glucose <100 mg/dL); NR II, normal fasting glucose group II (100≤fasting glucose <110 mg/dL); IFG, impaired fasting glucose group (110 ≤fasting glucose ≤125 mg/dL); DM, diabetes mellitus group (fasting glucose ≤126 mg/dL); HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; Lp(a), lipoprotein(a); hsCRP, high sensitivity C-reactive protein.
Table 2.
Pearson correlation coefficients between hsCRP and components of metabolic syndrome
Table 3.
Prevalence of number of components of the metabolic syndrome except abnormal fasting glucose level
XML Download